Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.31 | 1.01 | -0.42 | -0.07 |
| FCF Yield | -1.31% | -0.04% | -0.05% | -0.48% |
| EV / EBITDA | -1,136.20 | -206.31 | -181.85 | -19.97 |
| Quality | ||||
| ROIC | -2.12% | -0.16% | -0.13% | -0.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -2.76 | -0.09 | -0.13 | -0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -774.69% | 17.65% | 61.23% | 58.07% |
| Safety | ||||
| Net Debt / EBITDA | -1.57 | -0.01 | -0.14 | -0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |